CARLSBAD, Calif., July 10, 2024 (GLOBE NEWSWIRE) -- Aurora Spine Corporation ("Aurora Spine" or the "Company") (TSXV: ASG) (OTCQB: ASAPF), a designer and manufacturer of innovative medical devices that improve spinal surgery outcomes, today announced it will be participating in the Sixth Annual ASPN Conference sponsored by The American Society of Pain Neuroscience (ASPN) to be held July 11-14, 2024 at the Fontainebleau in Miami Beach, Florida. Aurora will be located at Booth 121.
On July 12th, at 10:15 a.m., Aurora Spine will be hosting a product theater debuting investigator-initiated real-world prospective clinical research on SILO TFX and ZIP 51. Pankaj Mehta MD, Steven Falowski MD, and Jason Pope MD will present a comparative analysis from Aurora Spine's Refine Study, the first multi-center, multi-specialty, randomized control trial for interlaminar fusion with neurosurgeons, ortho-spine surgeons, and intervention pain physicians.
Trent Northcutt, President and Chief Executive Officer of Aurora Spine, stated, "We are very excited to be participating in this year's ASPN Conference. We are proud to have an audience with thought-leading physicians to learn about Aurora's product portfolio and clinical evidence."
About Aurora Spine
Aurora Spine is focused on bringing new solutions to the spinal implant and pain markets through a series of innovative, minimally invasive, regenerative spinal implant technologies. Aurora Spine is an emerging growth company focused on bringing new solutions to the spinal implant and pain care markets through a series of screwless, innovative, minimally invasive, regenerative spinal implant technologies. Additional information can be accessed at or .
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This news release contains forward-looking information that involves substantial known and unknown risks and uncertainties, most of which are beyond the control of Aurora Spine, including, without limitation, those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Information" in Aurora Spine's final prospectus (collectively, "forward-looking information"). Forward-looking information in this news release includes information concerning the proposed use and success of the company's products in surgical procedures. Aurora Spine cautions investors of Aurora Spine's securities about important factors that could cause Aurora Spine's actual results to differ materially from those projected in any forward-looking statements included in this news release. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ unilaterally from those expressed in such forward-looking statements. No assurance can be given that the expectations set out herein will prove to be correct and, accordingly, prospective investors should not place undue reliance on these forward-looking statements. These statements speak only as of the date of this press release and Aurora Spine does not assume any obligation to update or revise them to reflect new events or circumstances.
Contact:
Aurora Spine Corporation
Trent Northcutt
President and Chief Executive Officer
(760) 424-2004
Chad Clouse
Chief Financial Officer
(760) 424-2004
